Analyzing Grail (NASDAQ:GRAL) and Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Celcuity and Grail, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0	0	6	1	3.14
Grail	0	0	0	0	N/A

Celcuity presently has a consensus price target of $28.67, suggesting a potential upside of 99.07%. Given Celcuity’s higher probable upside, equities research analysts clearly believe Celcuity is more favorable than Grail.

Institutional & Insider Ownership

63.3% of Celcuity shares are owned by institutional investors. 24.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Celcuity and Grail”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$63.78 million	($2.78)	-5.18
Grail	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Celcuity and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-60.83%	-40.57%
Grail	N/A	N/A	N/A

Summary

Celcuity beats Grail on 5 of the 7 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About Grail

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.